Indications & Uses
Ottomac Pouron (Vet) is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
For treatment (if COVIO positive), the dose of Ivermectin is 2 tablets of 6 mg once daily for 5 days (2+0+0 for 5 days). For prophylaxis, a single dose is taken on Day 1 and the same dose is repeated on Day 7. The dose depends on body weight: Body weight 15-24 kg: 1 tablet of Ivermectin 3 mg Body weight 25-35 kg: 1 tablet of Ivermectin 6 mg Body weight 36-50 kg: 1 tablet of Ivermectin 6 mg + 1 tablet of Ivermectin 3 mg Body weight 51-65 kg: 2 tablets of Ivermectin 6 mg Body weight 66-79 kg: 2 tablets of Ivermectin 6 mg + 1 tablet of Ivermectin 3 mg Body weight >80 kg: 3 tablets of Ivermectin 6 mg Strongyloidiasis The recommended dose of Ivermectin for strongyloidiasis is a single oral dose meant to provide approximately 200 mcg/kg of body weight. Patients should take the tablets on an empty stomach with water. In general, extra doses aren't needed. Follow-up stool examinations should still be done to confirm that the infection has been cleared. Dosage guidelines for Ivermectin in strongyloidiasis: Body weight (kg) 15-24: dose 3 mg/kg Body weight (kg) 25-35: dose 6 mg/kg Body weight (kg) 36-50: dose 9 mg/kg Body weight (kg) 51-65: dose 12 mg/kg Body weight (kg) 66-79: dose 15 mg/kg Body weight (kg) >80: dose 200 mcg/kg Onchocerciasis The recommended dose of Ivermectin is a single oral dose meant to provide approximately 150 mcg of Ivermectin per kg of body weight, taken on an empty stomach with water. The most commonly used dose interval is 12 months. For individual patients, retreatment may be considered at intervals as short as 3 months. Dosage guidelines for Ivermectin in onchocerciasis: Body weight (kg) 15-25: dose 3 mg/kg Body weight (kg) 26-44: dose 6 mg/kg Body weight (kg) 45-64: dose 9 mg/kg Body weight (kg) 65-84: dose 12 mg/kg Body weight (kg) >85: dose 150 mcg/kg
Side Effects
Strongyloidiasis: In four clinical studies covering a total of 109 patients who received one or two doses of 170 to 200 mcg/kg of Riovera, the following adverse reactions were reported as possibly, probably, or definitely related to Riovera. Body as a whole: asthenia/fatigue (0.9%), abdominal pain (0.9%). Gastrointestinal: anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%). Nervous System/Psychiatric: dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%). Skin: pruritus (2.8%), rash (0.9%), and urticaria (0.9%). Onchocerciasis: arthralgia/synovitis (19.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, respectively), cervical lymph node enlargement and tenderness (5.3% and 1.2%, respectively), inguinal lymph node enlargement and tenderness (12.6% and 13.9%, respectively), other lymph node enlargement and tenderness (3.0% and 1.9%, respectively), pruritus (27.5%), skin involvement including edema, papular and pustular or frank urticarial rash (22.7%), and fever (22.6%), along with abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, and chorioretinitis or choroiditis. These have rarely been severe or associated with loss of vision and have generally resolved without corticosteroid treatment. The following adverse reactions have been reported since the drug was registered overseas: hypotension (mainly orthostatic hypotension), worsening of bronchial asthma, toxic epidermal necrolysis, and Stevens-Johnson syndrome.
Cautions & Contraindications
Warnings & Precautions
Older studies on microfilaricidal drugs, such as diethylcarbamazine citrate (DEC-C), found that they can cause skin and/or whole-body reactions of varying severity (the Mazzotti reaction), as well as eye reactions, in people with onchocerciasis. These reactions are thought to come from allergic and inflammatory responses to the dying microfilariae. People treated with Riovera for onchocerciasis may get these reactions, along with other side effects that may, probably, or definitely be caused by the drug itself. Severe Mazzotti reactions have not been studied in controlled clinical trials, so there is no proven standard treatment for them. For low blood pressure on standing (postural hypotension), oral fluids, lying down, intravenous normal saline, and/or corticosteroids given by injection have been used. Antihistamines and/or aspirin have been used for most mild to moderate cases. People with hyperreactive onchodermatitis (sowda) are more likely than others to have severe reactions after treatment with microfilaricidal drugs. Swelling and worsening of the onchodermatitis are the main concerns here. Rarely, people with onchocerciasis who also have a heavy Loa loa infection can develop a serious and sometimes fatal brain condition called encephalopathy. This can happen on its own or after treatment with an effective microfilaricide. In these patients, the following have also been reported: back pain, bleeding in the white of the eye (conjunctival hemorrhage), shortness of breath (dyspnea), loss of control of urine and/or stool, trouble standing or walking, changes in mental state, confusion, lethargy, stupor, or coma.
Contraindications
Do not use this medicine if you are allergic to any of its ingredients.